Non-hormonal Management Options — MCQs
A 46-year-old woman presents for her annual examination. Her main complaint is frequent sweating episodes with a sensation of intense heat starting at her upper chest and spreading up to her head. These have been intermittent for the past 6 to 9 months but are gradually worsening. She has three to four flushing/sweating episodes during the day and two to three at night. She occasionally feels her heart race for about a second, but when she checks her pulse it is normal. She reports feeling more tired and has difficulty with sleep due to sweating. She denies major life stressors. She also denies weight loss, weight gain, or change in bowel habit. Her last menstrual cycle was 3 months ago. Physical examination is normal. Which treatment is most appropriate in alleviating this woman's symptoms?
Which of the following is the platinum-based chemotherapeutic agent used as first-line treatment for ovarian carcinoma?
What is the most common symptom treated with hormone therapy (HT) in menopausal women?
Which of the following is an indication for use of Hormone Replacement Therapy in menopausal women:-
What is the definitive management for adenomyosis?
Which of the following hormones increases during the postmenopausal period?
Which of the following statements about the postmenopausal state is false?
Which of the following is NOT a recommended primary management option for a patient with a snake bite?
Which of the following is NOT an indication for postoperative radiotherapy in a case of carcinoma endometrium?
Hormone replacement therapy can increase the risk of which of the following conditions?
Non-hormonal Management Options Indian Medical PG Practice Questions and MCQs
Question 1: A 46-year-old woman presents for her annual examination. Her main complaint is frequent sweating episodes with a sensation of intense heat starting at her upper chest and spreading up to her head. These have been intermittent for the past 6 to 9 months but are gradually worsening. She has three to four flushing/sweating episodes during the day and two to three at night. She occasionally feels her heart race for about a second, but when she checks her pulse it is normal. She reports feeling more tired and has difficulty with sleep due to sweating. She denies major life stressors. She also denies weight loss, weight gain, or change in bowel habit. Her last menstrual cycle was 3 months ago. Physical examination is normal. Which treatment is most appropriate in alleviating this woman's symptoms?
- A. Estrogen plus progesterone (Correct Answer)
- B. Citalopram
- C. Estrogen
- D. Levothyroxine
Explanation: ***Estrogen plus progesterone*** - This patient's symptoms (hot flashes, night sweats, fatigue, sleep disturbance, irregular menses) are highly suggestive of **perimenopause/menopause**. **Hormone replacement therapy (HRT)** with estrogen and progesterone is the most effective treatment for managing severe menopausal symptoms. - Adding **progesterone** is crucial for women with an intact uterus to prevent **endometrial hyperplasia** and **endometrial cancer** caused by unopposed estrogen therapy. *Citalopram* - **Selective serotonin reuptake inhibitors (SSRIs)** like citalopram can reduce the frequency and severity of hot flashes, but they are generally reserved for women who cannot take or prefer not to take HRT due to contraindications or concerns. - SSRIs are less effective than HRT for severe vasomotor symptoms and do not address other menopausal symptoms like vaginal dryness or bone loss. *Estrogen* - While estrogen is the primary hormone for alleviating menopausal symptoms, administering **unopposed estrogen** to a woman with an intact uterus significantly increases the risk of **endometrial hyperplasia** and **endometrial carcinoma**. - Progesterone is necessary to counteract the proliferative effects of estrogen on the endometrium, preventing these risks. *Levothyroxine* - **Levothyroxine** is used to treat **hypothyroidism**, a condition that can cause fatigue, weight changes, and menstrual irregularities. - However, the patient's primary symptoms of prominent hot flashes and night sweats are not characteristic of hypothyroidism, and her physical examination is normal, making this diagnosis less likely.
Question 2: Which of the following is the platinum-based chemotherapeutic agent used as first-line treatment for ovarian carcinoma?
- A. Cyclophosphamide
- B. Methotrexate
- C. Cisplatin (Correct Answer)
- D. Dacarbazine
Explanation: ***Cisplatin*** - **Cisplatin** is a platinum-based chemotherapy drug that forms **DNA cross-links**, inhibiting DNA synthesis and leading to the death of rapidly dividing cells, making it highly effective against **ovarian carcinoma**. - It is a cornerstone of chemotherapy regimens for ovarian cancer, often used in combination with other agents such as paclitaxel. *Methotrexate* - **Methotrexate** is an **antimetabolite** that inhibits dihydrofolate reductase, thereby interfering with DNA synthesis. - While it is used in various cancers like leukemia, lymphoma, and some solid tumors (e.g., breast cancer, gestational trophoblastic disease), it is **not a primary recommended drug for ovarian carcinoma**. *Cyclophosphamide* - **Cyclophosphamide** is an **alkylating agent** that causes DNA damage, leading to cell death. - It is used in many cancers, including lymphoma, breast cancer, and some leukemias, but it is **not a first-line or primary agent for ovarian carcinoma** in contemporary treatment guidelines. *Dacarbazine* - **Dacarbazine** is an **alkylating agent** primarily used in the treatment of **malignant melanoma** and Hodgkin lymphoma. - It is **not indicated for the treatment of ovarian carcinoma**.
Question 3: What is the most common symptom treated with hormone therapy (HT) in menopausal women?
- A. Endometriosis
- B. Uterine bleeding
- C. Hot flashes (Correct Answer)
- D. Breast cancer
Explanation: ***Hot flashes*** - **Vasomotor symptoms**, including hot flashes and night sweats, are the most frequent and bothersome symptoms experienced by menopausal women, leading them to seek medical attention and hormone therapy. - HT is highly effective in reducing the frequency and severity of hot flashes by stabilizing **thermoregulation** in the hypothalamus. *Breast cancer* - **Breast cancer** is a potential risk associated with hormone therapy, particularly with combined estrogen-progestin therapy, not a symptom treated by HT. - Women with a history of breast cancer or those at high risk are generally advised against HT due to this increased risk. *Endometriosis* - While **estrogen-dependent diseases** like endometriosis can be aggravated by HRT, endometriosis itself is a condition that typically improves after menopause. - HT is not used to treat endometriosis; in certain cases, it might be used to manage menopausal symptoms in women with a history of endometriosis after specific surgical interventions. *Uterine bleeding* - **Uterine bleeding** can be a side effect of hormone therapy, especially when progestin is not adequately balanced with estrogen in women with a uterus. - Abnormal uterine bleeding is a symptom that requires investigation to rule out other causes, and it is not a primary symptom treated by HT.
Question 4: Which of the following is an indication for use of Hormone Replacement Therapy in menopausal women:-
- A. Post menopausal bleeding
- B. Hot flushes (Correct Answer)
- C. Cardiovascular protection
- D. Pyelonephritis
Explanation: ***Hot flushes*** - Hormone Replacement Therapy (HRT) is highly effective in alleviating **vasomotor symptoms** like hot flushes and night sweats, which can severely impact quality of life in menopausal women. - The primary goal of using HRT is to manage these **menopausal symptoms** when they are bothersome. *Post menopausal bleeding* - **Postmenopausal bleeding** is a contraindication, not an indication, for new HRT initiation as it requires investigation to rule out endometrial pathology, including cancer. - If a woman on HRT experiences bleeding, it warrants immediate investigation to determine its cause and may necessitate stopping or changing the HRT regimen. *Cardiovascular protection* - While earlier beliefs suggested HRT offered cardiovascular protection, current evidence, particularly from the **Women's Health Initiative (WHI) study**, showed that HRT does not provide primary or secondary cardiovascular protection. - In fact, HRT may increase the risk of **cardiovascular events** like stroke and venous thromboembolism, especially when initiated many years after menopause. *Pyelonephritis* - **Pyelonephritis** is an infection of the kidney, typically caused by bacteria, and is not directly related to menopausal symptoms or hormonal status. - Treatment for pyelonephritis involves **antibiotics** and supportive care, not HRT.
Question 5: What is the definitive management for adenomyosis?
- A. Endometrial ablation.
- B. Hysterectomy (surgical removal of the uterus). (Correct Answer)
- C. Hormonal therapy (e.g., Danazol) for temporary symptom relief.
- D. Hormonal therapy (e.g., GnRH analogue) for temporary symptom relief.
Explanation: ***Hysterectomy (surgical removal of the uterus)*** - This is considered the **definitive management** for adenomyosis because it completely removes the uterine tissue where the ectopic endometrial glands are found. - Hysterectomy effectively eliminates the source of symptoms such as **heavy menstrual bleeding** and **pelvic pain** by removing the uterus entirely. *Endometrial ablation* - Endometrial ablation involves destroying the **lining of the uterus** and is primarily used for heavy menstrual bleeding. - It is **ineffective for adenomyosis** since the endometrial tissue is embedded deep within the myometrium and is not fully reached by ablation. *Hormonal therapy (e.g., Danazol) for temporary symptom relief* - **Danazol** (an androgen derivative) can suppress ovarian function and reduce symptoms of adenomyosis by shrinking endometrial tissue. - However, its effects are **temporary**, and symptoms typically return upon cessation of treatment, making it not a definitive solution. *Hormonal therapy (e.g., GNRH analogue) for temporary symptom relief* - **GnRH analogues** induce a temporary menopausal state, which can significantly reduce symptoms by inhibiting estrogen production, leading to atrophy of the adenomyotic tissue. - This treatment is also **temporary**, and symptoms often recur once the medication is stopped; it's often used as a bridge to surgery or for women nearing menopause.
Question 6: Which of the following hormones increases during the postmenopausal period?
- A. Progesterone
- B. Estrogen
- C. FSH (Correct Answer)
- D. Androgens
Explanation: ***FSH*** - In **postmenopausal women**, the ovaries no longer produce significant amounts of **estrogen** and **progesterone**. - This lack of negative feedback on the **hypothalamus** and **pituitary gland** leads to a compensatory increase in **gonadotropin-releasing hormone (GnRH)**, which, in turn, stimulates the pituitary to produce more **FSH** and to a lesser extent, **LH**. *Progesterone* - **Progesterone levels decline** significantly after menopause as ovulation ceases. - The **corpus luteum**, which produces progesterone after ovulation, is no longer formed. *Estrogen* - **Estrogen levels decline dramatically** after menopause due to the cessation of ovarian follicular activity. - This decrease in estrogen is responsible for many menopausal symptoms, such as **hot flashes** and **vaginal dryness**. *Androgens* - While **ovarian androgen production** decreases, **adrenal androgen production** (e.g., **DHEA** and **androstenedione**) continues. - However, overall **androgen levels tend to decrease slightly** but not as dramatically as estrogen or progesterone, and they do not increase.
Question 7: Which of the following statements about the postmenopausal state is false?
- A. High FSH
- B. Low LH (Correct Answer)
- C. Low estrogen
- D. High androgen
Explanation: ***Low LH*** - This statement is **FALSE** because **LH (luteinizing hormone) levels are markedly elevated** in postmenopausal women. - The drop in ovarian estrogen production removes the **negative feedback** on the pituitary, leading to **increased LH and FSH secretion**. - Both gonadotropins (LH and FSH) are characteristically **high in postmenopause**. *High FSH* - This statement is true; **FSH (follicle-stimulating hormone) levels are markedly elevated** in postmenopausal women. - The elevated FSH is a direct consequence of the **lack of negative feedback** from inhibin and estrogen produced by the ovaries. *Low estrogen* - This statement is true; **estrogen levels plummet significantly** after menopause due to the **cessation of ovarian follicular activity**. - This **estrogen deficiency** is responsible for many postmenopausal symptoms, such as hot flashes, vaginal atrophy, and bone loss. *High androgen* - While androgens are still produced by the adrenal glands and ovaries postmenopause, their **absolute levels also decline with age**. - The statement is somewhat ambiguous, but androgens do **not increase** in absolute terms; rather, the **estrogen-to-androgen ratio changes** because estrogen falls more dramatically.
Question 8: Which of the following is NOT a recommended primary management option for a patient with a snake bite?
- A. Wash with soap and water (Correct Answer)
- B. Reassure the patient
- C. Splinting and immobilization
- D. Keep the site of bite below heart level
Explanation: ***Wash with soap and water*** - Washing the bite with soap and water is **NOT** a recommended primary management option for a snake bite as it can spread the **venom**, potentially worsening the local effects and systemic absorption [1]. - The focus should be on **immobilization and minimizing movement** to restrict venom spread [1], [3]. *Splinting and immobilization* - **Immobilization** of the bitten limb is crucial to reduce venom dissemination through the **lymphatic system** [1], [2]. - This helps to **slow the absorption** of venom into the systemic circulation [1], [3]. *Reassure the patient* - **Anxiety and panic** can increase heart rate and metabolism, potentially accelerating venom absorption. - **Reassurance** helps to calm the patient, which can slow the spread of venom and improve cooperation with treatment [1], [2]. *Keep the site of bite below heart level* - Keeping the affected limb **below heart level** helps to reduce blood flow and, consequently, the systemic spread of venom [1]. - This simple maneuver can **delay the onset** of systemic toxic effects [1].
Question 9: Which of the following is NOT an indication for postoperative radiotherapy in a case of carcinoma endometrium?
- A. Positive lymph nodes
- B. Endocervical involvement
- C. Myometrial invasion >1/2 thickness
- D. Tumour positive for estrogen receptors (Correct Answer)
Explanation: ***Tumour positive for estrogen receptors*** - **Estrogen receptor (ER) positivity** in endometrial cancer is a favorable prognostic factor, indicating a more differentiated tumor and potential responsiveness to hormonal therapies, not an indication for radiotherapy. - Tumors with **positive ER status** are often treated with anti-estrogen therapies like progestins, especially in advanced or recurrent disease. *Myometrial invasion >1/2 thickness* - **Deep myometrial invasion** (>1/2 thickness) signifies a higher risk of lymphatic spread and recurrence, making postoperative radiotherapy a crucial adjunct to reduce local and regional recurrence. - This finding is a significant **"intermediate-risk" or "high-risk" factor** depending on other clinicopathological features, prompting consideration of external beam radiation therapy (EBRT) or vaginal brachytherapy. *Positive lymph nodes* - The presence of **positive lymph nodes** (pelvic or para-aortic) indicates systemic disease and a high risk of recurrence, necessitating adjuvant treatment including chemotherapy and/or radiotherapy. - **Node-positive disease** is a strong indication for comprehensive adjuvant therapy, with radiotherapy targeting the pelvic and/or para-aortic nodal beds. *Endocervical involvement* - **Endocervical stromal involvement** (FIGO Stage II) is an adverse prognostic factor, increasing the risk of local recurrence and making postoperative radiotherapy (typically vaginal brachytherapy, often with pelvic EBRT) a standard recommendation. - This finding elevates the disease stage and requires more aggressive adjuvant local treatment to control microscopic disease in the cervix and upper vagina.
Question 10: Hormone replacement therapy can increase the risk of which of the following conditions?
- A. Osteoporosis
- B. Breast carcinoma (Correct Answer)
- C. Alzheimer's disease
- D. Colorectal cancer
Explanation: **Explanation:** The correct answer is **Breast carcinoma**. Hormone Replacement Therapy (HRT), specifically the combined estrogen-progestogen regimen, is associated with an increased risk of breast cancer. This risk is duration-dependent, typically becoming significant after 3–5 years of use. Estrogen promotes the proliferation of mammary epithelial cells, and the addition of progestogen further enhances this mitogenic effect, potentially promoting the growth of pre-existing occult tumors. **Analysis of Incorrect Options:** * **A. Osteoporosis:** HRT is actually **protective** against osteoporosis. Estrogen inhibits osteoclast activity and reduces bone resorption, thereby increasing bone mineral density and reducing the risk of fractures. * **C. Alzheimer’s Disease:** Current evidence suggests HRT does not increase the risk; some studies even suggest a "window of opportunity" where early initiation may be neuroprotective, though it is not indicated for dementia prevention. * **D. Colorectal Cancer:** Combined HRT has been shown to **decrease** the risk of colorectal cancer (by approximately 30% according to the Women's Health Initiative study). **High-Yield Clinical Pearls for NEET-PG:** * **WHI Study Findings:** HRT increases the risk of **Breast Cancer, Stroke, Venous Thromboembolism (VTE), and Coronary Heart Disease (CHD)**. * **Protective Effects:** HRT decreases the risk of **Osteoporotic fractures and Colorectal cancer**. * **Endometrial Cancer:** Unopposed estrogen increases the risk of endometrial cancer; therefore, progestogen must be added in women with an intact uterus. * **Indications:** The primary indication for HRT is the management of moderate-to-severe vasomotor symptoms (hot flashes) and urogenital atrophy.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free